Latest News for: 032
Edit
Selective varicella (chickenpox) catch-up vaccination programme from 1 November 2026 (WHC/2026/032) (Welsh Government)
Public Technologies 05 Oct 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 134953778) .
Edit
Smith+Nephew announces results of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 (Form 6-K) (Smith & Nephew plc)
Public Technologies 16 Sep 2026
Smith+Nephew announces results of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 ... 2.032% Senior Notes due 2030 (Maturity date.
Edit
Smith+Nephew announces pricing of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 (Form 6-K) (Smith & Nephew plc)
Public Technologies 16 Sep 2026
Smith+Nephew announces pricing of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 ... 2.032% Senior Notes due 2030 (Maturity date.
Edit
Morgan Citizen
14 Jul 2026
Hyperscale Data Bitcoin Treasury Reaches 1,032 Bitcoin Worth Approximately $65.8 Million and Acquired 130 Bitcoin ...
Edit
Hyperscale Data Bitcoin Treasury Reaches 1,032 Bitcoin Worth Approximately $65.8 Million and Acquired 130 Bitcoin During the Week Ended July 12, 2026
PR Newswire 12 Jul 2026
Edit
Assam schools face twin challenge: 32,321 have fewer than 30 students, 60,032 teacher posts vacant
The Times of India 10 Jul 2026
Edit
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
Business Wire 02 Jul 2026
... potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis.
Edit
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis (Form 8-K) (Arcturus Therapeutics Holdings Inc)
Public Technologies 02 Jul 2026
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis ... of ARCT-032, Arcturus' investigational mRNA therapy for Cystic Fibrosis.
- 1